Sign in Subscribe
Chronic obstructive lung disease

Proteomics-Based Risk Prediction and Drug Targets Identification for Chronic Obstructive Pulmonary Disease

Strategic Insights

— 1 min read

Chronic obstructive pulmonary disease (COPD) is a leading cause of global mortality, yet existing risk prediction models remain limited. A recent study published in Thorax has developed and validated a protein-based risk score for COPD, comparing its performance against COPD polygenic risk scores (PRSs) and clinical risk factors. The study analyzed 27,796 UK Biobank participants and identified predictive proteins in the training set, with a 32-protein risk score strongly predicting incident COPD with high accuracy.

Key Takeaways:

  • The study developed and validated a 32-protein risk score for COPD, which outperformed PRSs and matched clinical models in predicting incident COPD.
  • The 32-protein risk score had a C-index of 0.826, 95% CI 0.803 to 0.849, compared to 0.510, 95% CI 0.478 to 0.542 for PRSs.
  • Adding protein scores to clinical factors improved risk reclassification, with NRI ranging from 0.251 to 0.318 and IDI ranging from 0.042 to 0.064.
  • The study identified ADM and SCGB1A1 as protective proteins, while MMP12 and TNFRSF10A increased risk, and implicated inflammation and extracellular remodelling pathways.
  • Chitinase-3-like protein 1 and matrix metalloproteinase-9 were central players in the protein-protein interaction network.
  • The study identified novel pathways and causal therapeutic targets for COPD.

Statistics:

  • 27,796 UK Biobank participants were analyzed in the study.
  • 32 proteins were identified as predictive of COPD risk.
  • The C-index for the 32-protein risk score was 0.826, 95% CI 0.803 to 0.849.
  • The C-index for PRSs was 0.510, 95% CI 0.478 to 0.542.
  • NRI ranged from 0.251 to 0.318 for the 32-protein risk score.
  • IDI ranged from 0.042 to 0.064 for the 32-protein risk score.

Sources:

  • NewsRx. Findings from Southern Medical University Update Understanding of Chronic Obstructive Pulmonary Disease (Proteomics-based Risk Prediction and Drug Targets Identification for Chronic Obstructive Pulmonary Disease). Genomics & Genetics Weekly. October 31, 2025; p 557.
  • Proteomics-based Risk Prediction and Drug Targets Identification for Chronic Obstructive Pulmonary Disease. Thorax, 2025.

Read more